In a highly competitive space, AI platforms must now prove themselves through proprietary data, focused pipelines and clinical readouts in competitive diseases. Promises of faster, cheaper drug discovery are not enough to entice strong investor engagement.
With an expanding number of AI platforms promising to deliver faster, cheaper drug discovery, there is a high investor bar that defines success. Investors argue the winners will be defined not by clever models, but by pipelines, proprietary data and strong clinical readouts.
Native AI-driven discovery is appealing because it compresses early discovery cycles, but it must also deliver biological insight and real drugs to create durable value, said Akshay Rai, principal, Healthcare & Biotech Investments at Premji Invest. Although there is palpable excitement in the healthcare ecosystem, it is gated by disciplined milestones, deal structures and sophisticated investors’ proof-point expectations, he said.
The bar for new AI-biotech companies is high on technology application and platform traction, Rai added. Iterative platform learning, strong prospective predictive power (e.g., structure prediction validated experimentally) and credible biological translation, are crucial to garner investor interest, he added.
Competitive AI Drug Discovery Market
The emergence of Recursion Pharmaceuticals a decade ago spawned multiple me-too AI platform companies, with “everyone claiming they can drug undruggable targets,” as well as do it faster and cheaper, said Anna Marie Detert, principal at Gloucester Ventures. But many of these platforms struggle to have outcomes that pharma can recognize, she said. Unless these platforms can generate assets or tie into a pipeline, “they’re not going anywhere,” Detert said.
One success story is Enveda, which announced in September 2025 that it raised $150 million in a Series D round, led by Premji. This brings its total funding to $517 million and the company has a $1 billion valuation, now granted “unicorn” status. Enveda has developed an AI platform that identifies and decodes molecules inside of plants and natural sources and then predicts which of those molecules might become useful medicines.
ENV-294 is completing Phase Ib trials and has initiated Phase IIa trials in atopic dermatitis. Phase IIa trials in asthma following IND clearance have also started.
The company purposely targeted large, crowded markets (e.g., atopic dermatitis, obesity, IBD, liver disease), with future clinical read-outs to reinforce that the platform repeatedly produces valuable assets, Enveda’s CEO and Founder Viswa Colluru.
He concurred with Rai that platform claims must make a case in differentiated clinical data in competitive indications, not just in internal metrics or rare disease niches. Ultimately patient benefit and clinical outcomes will garner more interest rather than tech alone, they agreed.
AI Founder Faux Pas
Founders often prioritize model sophistication while neglecting proprietary data, Colluru and Rai said, which is the ultimate determinate of value. There can be an underestimation of translational challenges; robust animal models and human relevance is needed.
Too many AI companies lead with technology, rather than the issue to solve, said René Bastón, venture partner at Covenant Venture Capital. “When I evaluate a startup, I start with three questions: What specific problem are you solving? Can you show me clean metrics that matter? And can you actually get paid for it in the messy reality of healthcare?” he posed.
Another miss, Rai and Colluru said, is having too many platform indications and candidates rather than focused on a few that can generate specific, high-value validation.
“The companies winning right now aren’t the ones with the flashiest models: they’re the ones with focused use cases, clear business models and a real path to deployment,” Bastón added.
Finally, partnership-loaded models can distract and dilute economics. Teams must evaluate whether they are a pharma services or platform partner or a drug company that owns its pipeline, Rai and Colluru said.
These considerations are important in an environment where capital is increasingly concentrated, and fewer companies are raising significant rounds earlier in their life cycle, Rai said.
You can hear more on this week’s Denatured podcast episode.
